top

  Info

  • Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.

  Info

  • Utilizzare questo link per rimuovere la selezione effettuata.
Advances in antiviral drug design . Volume 5 [[electronic resource] /] / editor, E. De Clercq
Advances in antiviral drug design . Volume 5 [[electronic resource] /] / editor, E. De Clercq
Pubbl/distr/stampa Greenwich, CT ; ; London, England, : Jai Press, 2007
Descrizione fisica 1 online resource (265 p.)
Disciplina 616.9
616.9/25061/05
616.91061
Altri autori (Persone) De ClercqErik
Collana Advances in antiviral drug design
Soggetto topico Antiviral agents
Anti-infective agents
Soggetto genere / forma Electronic books.
ISBN 1-281-11983-0
9786611119836
0-08-054824-5
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Nota di contenuto I. IntroductionII. Design; III. Synthesis; IV. Antiviral activity; Acknowledgements; References; Chapter 4. Synthesis and antiviral evaluation of broad spectrum, orally active analogs of cidofovir and other acyclic nucleoside phosphonates; I. Introduction; II. Synthesis of hexadecyloxypropyl and related esters of cidofovir; III. Antiviral evaluation and spectrum of activity; IV. Structure activity relationships; V. Cellular metabolism; VI. Oral pharmacokinetics and tissue distribution; VII. Antiviral activity in animal models of viral diseases
VIII. Alkoxyalkyl esters of (S)-HPMPA and other acyclic nucleoside phosphonatesIX. Conclusions; Acknowledgements; References; Chapter 5. CCR5 antagonistsCCR5 antagonists for the treatment ofHIV infection and AIDS; I. Introduction; II. Inhibition of HIV entry; III. CCR5 as a drug target; IV. The discovery of novel CCR5 antagonists; V. Molecular mechanisms; VI. Resistance to CCR5 antagonists in vitro and in the clinic; VII. Conclusions; References; Chapter 6. The medicinal chemistry of the DATADATA and DAPYDAPY series of HIV-1HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIsNNRTIs)
AbstractI. Introduction; II. The diaryltriazine (DATA) series; III. The diarylpyrimidine (DAPY) series; IV. Conclusion; Acknowledgements; References; Index
Record Nr. UNINA-9910457252903321
Greenwich, CT ; ; London, England, : Jai Press, 2007
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Advances in antiviral drug design . Volume 5 [[electronic resource] /] / editor, E. De Clercq
Advances in antiviral drug design . Volume 5 [[electronic resource] /] / editor, E. De Clercq
Pubbl/distr/stampa Greenwich, CT ; ; London, England, : Jai Press, 2007
Descrizione fisica 1 online resource (265 p.)
Disciplina 616.9
616.9/25061/05
616.91061
Altri autori (Persone) De ClercqErik
Collana Advances in antiviral drug design
Soggetto topico Antiviral agents
Anti-infective agents
ISBN 1-281-11983-0
9786611119836
0-08-054824-5
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Nota di contenuto I. IntroductionII. Design; III. Synthesis; IV. Antiviral activity; Acknowledgements; References; Chapter 4. Synthesis and antiviral evaluation of broad spectrum, orally active analogs of cidofovir and other acyclic nucleoside phosphonates; I. Introduction; II. Synthesis of hexadecyloxypropyl and related esters of cidofovir; III. Antiviral evaluation and spectrum of activity; IV. Structure activity relationships; V. Cellular metabolism; VI. Oral pharmacokinetics and tissue distribution; VII. Antiviral activity in animal models of viral diseases
VIII. Alkoxyalkyl esters of (S)-HPMPA and other acyclic nucleoside phosphonatesIX. Conclusions; Acknowledgements; References; Chapter 5. CCR5 antagonistsCCR5 antagonists for the treatment ofHIV infection and AIDS; I. Introduction; II. Inhibition of HIV entry; III. CCR5 as a drug target; IV. The discovery of novel CCR5 antagonists; V. Molecular mechanisms; VI. Resistance to CCR5 antagonists in vitro and in the clinic; VII. Conclusions; References; Chapter 6. The medicinal chemistry of the DATADATA and DAPYDAPY series of HIV-1HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIsNNRTIs)
AbstractI. Introduction; II. The diaryltriazine (DATA) series; III. The diarylpyrimidine (DAPY) series; IV. Conclusion; Acknowledgements; References; Index
Record Nr. UNINA-9910784598503321
Greenwich, CT ; ; London, England, : Jai Press, 2007
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Viral Drug Delivery Systems : Advances in Treatment of Infectious Diseases / / edited by Ranjita Shegokar, Yashwant Pathak
Viral Drug Delivery Systems : Advances in Treatment of Infectious Diseases / / edited by Ranjita Shegokar, Yashwant Pathak
Edizione [1st ed. 2023.]
Pubbl/distr/stampa Cham : , : Springer International Publishing : , : Imprint : Springer, , 2023
Descrizione fisica 1 online resource (X, 409 p. 53 illus., 47 illus. in color.)
Disciplina 615.6
616.91061
Soggetto topico Drug delivery systems
Pharmaceutical chemistry
Diseases
Pharmacology
Epidemiology
Pharmacy
Drug Delivery
Pharmaceutics
ISBN 3-031-20537-5
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Nota di contenuto Global health and Viral diseases past, present and Future -- Drug resistance and statistics and patent status -- cellular understanding viral diseases -- Viral: current treatment options -- Mucosal drug delivery strategies for antiviral intervention -- Micro, nano emulsions in viral -- Novel formulation approaches to treat Ebola- virus -- Ebola- drug delivery -- Polymers for Bio sensing Applications in antiviral therapy and diagnosis -- Nanotechnology: A Stepping Stone towards Viral Hepatitis Treatment and Prevention in Children -- Recent Developments in the Treatment of Influenza -- Covid 19: from molecular pathogenesis to potential repurposed treatments -- Nano drug delivery systems for Covid-19-drug delivery -- Exploring the link between malaria and Covid 19 -- Characterization of biofunctionalized nanoparticles in ID -- Covid- azithromycin-ritonavir -- Strategies to combat Covid-19 drug delivery -- Phytomolecules and NDDS Covid-19.
Record Nr. UNINA-9910686478003321
Cham : , : Springer International Publishing : , : Imprint : Springer, , 2023
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui